IOWA HEALTH CARE

Clinical Trials Flowcharts

March 2025

CHANGING MEDICINE.
CHANGING LIVES.®

Table of Contents

To refer a patient:

To learn more about a specific trial, contact the MOG leader listed, or call the clinical trials hotline at 319-353-8155.

All calls to the clinical trials hotline will be returned within 48 hours.

The clinical trials team will then work with you to get your patient enrolled, when appropriate.

Clinical Trials Hotline

319-353-8155

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Breast Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

BREAST CANCER

OPEN

PENDING

NEOADJUVANT TNBC

SCARLET: T2-T4, N0, M0 or T1-T3, N1-2, M0; no prior systemic therapy or radiation therapy with curative intent for current breast cancer

PI: Sneha Phadke

NCT05929768

BREAST CANCER



BREAST CANCER

OPEN PENDING



BREAST CANCER

OPEN PENDING



BREAST CANCER

OPEN

PENDING



Gastrointestinal Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

PANCREATIC CANCER

NON-RESECTABLE

TIGER-PAC/RENOVO
Criteria: Histo/ctyo confirmed diagnosis within 6 weeks of consent; no prior treatment for pancreatic cancer OR more than 1 cycle of gem delivery and nab-paclitaxel; no evidence of metastatic disease; arterial anatomy suitable of intra-arterial of gemcitabine to intended tumor

PI: Naomi Fei

NCT05249101

LuMIERE:
Eligible for FOLFIRINOX. CrCl ≥ 60 mL/min, measurable disease.

PI: Yusuf Menda

NCT04939610

METASTATIC

TWINPEAK
Criteria: 1L Locally advanced or metastatic pancreatic adenocarcinoma; measurable disease

PI: Naomi Fei

NCT05482893

CG-745-2-08
Criteria: Locally advanced or metastatic pancreatic adenocarcinoma without evidence of progression on initial chemo for metastatic disease (CR, PR or SD); FOLFIRINOX at full or modified dose for a minimum of 16 wks with no evidence of progression

PI: Naomi Fei

NCT05249101

LuMIERE:
CrCl ≥ 60 mL/min, progressed on ≤ 2 prior chemotherapy regimens (changing for toxicity does not count), measurable disease.

PI: Yusuf Menda

NCT04939610

KO-2806
Criteria: KRAS G12C positive; prior KRAS use permitted

PI: Doug Laux

NCT06026410

COLORECTAL CANCER

OPEN

PENDING

NEOADJUVANT

Dostarlimab
Criteria: Biopsy proven Stage II or III dMMR amenable to en block surgical resection; biopsy specimen has enough tissue for 4-6 FFPE slides; absence of metastatic disease

PI: Saima Sharif

NCT05239546

ADJUVANT

NRG-GI008
Criteria: T1-3, N1/N1c confirmed adenocarcinoma with RO resection; no radiographic evidence of overt metastatic disease; distal extent of tumor ≥12 cm from anal verge on colonoscopy or above peritoneal reflection as documented during surgery or on path specimen; must have had en bloc complete gross resection of tumor (curative resection); microsatellite stable or intact mismatch repair proteins through CLIA approved testing

PI: Saima Sharif

NCT05174169

COLORECTAL CANCER

OPEN PENDING



GASTRIC/GASTROESPHAGEAL CANCER



HEPATOCELLULAR CARCINOMA

OPEN

PENDING



Genitourinary Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

BLADDER CANCER

NMIBC

Adapt
Criteria: Histologically confirmed urothelial carcinoma of bladder (Ta, T1, or Tis) on TURBT; BCG unresponsive disease (persistent CIS with or without the presence of Ta or T1 tumors within 12 months of completion of BCG, or recurrent high-grade Ta or T1 tumors within 6 months of completion of adequate BCG therapy

PI: Michael O'Donnell

NCT03317158

Bridge
Criteria: High-grade non-muscle invasive urothelial carcinoma of the bladder; must have all visible papillary tumor resected by the treating urologist at the site registering the patient; no prior intravesical therapy for bladder cancer with the exception of perioperative chemotherapy at the time of TURBT

PI: Michael O'Donnell

NCT05538663

NEOADJUVANT

EA8192
Criteria: High grade upper tract urothelial carcinoma proven by biopsy with 12 weeks of randomization; no component of small cell/neuroendocrine carcinoma; no evidence of metastatic disease or enlarged LN

PI: Umar Farooq

NCT04628767

V940-005
Criteria: muscle-invasive urothelial carcinoma

PI: Mohammed Milhem

NCT06305767

ADJUVANT

V940-005
Criteria: muscle-invasive urothelial carcinoma; high-risk pathologic disease after radical resection

PI: Mohammed Milhem

NCT06305767

BLADDER CANCER

OPEN PENDING



PROSTATE CANCER



METASTATIC HORMONE SENSITIVE

S1802
Criteria: Adenocarcinoma of prostate; no prior local therapy for prostate adenocarcinoma; evidence of metastatic disease on bone scan and CT or MRI; received no more than 28 weeks of standard systemic therapy(SST); no progression while on SST; must have surgically resectable disease per urology consult

PI: Joseph Caster

NCT03678025

METASTATIC CRPC

MK-5684-003
Criteria: Adenocarcinoma of prostate; progression while on ADT; has progressed on 1 novel hormonal agent; has received at least 1 but no more than 2 taxane based chemo regimens for metastatic CRPC

PI: Doug Laux

NCT06136624

Alphabreak:
Criteria: Open label, non-randomized. CrCl ≥ 60 mL/min, progressed after ≥2 of Pluvicto, no liver mets (phase 2), measurable disease

PI: Yusuf Menda

coPI: Kristin Plichta

NCT06402331

KIDNEY CANCER

OPEN

PENDING



KIDNEY CANCER

OPEN

PENDING



Gynecologic Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

OVARIAN CANCER

LOW GRADE SEROUS CARCINOMA

NRG-GY019 :
Criteria: Newly diagnosed, stage II-IV low-grade serous ovarian, fallopian tube and primary peritoneal cancers; must have undergone an attempt at maximal upfront cytoreductive surgery, with either optimal (=< 1 cm diameter residual disease/nodule) or suboptimal residual disease (> 1 cm diameter residual disease/nodule) allowed; must enroll within 8 weeks of primary surgery

PI: David Bender

NCT04095364

HIGH GRADE SEROUS CARCINOMA

GOG-3078-GLORIOSA (Maintenance therapy):
Criteria: Recurrent (1st recurrence), platinum-sensitive high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer; FRα-High; subjects who have not progressed after second-line platinum-based chemotherapy plus bevacizumab; prior PARP required if BRCA mutated; must be randomized within 8 weeks from last dose of platinum-based triplet therapy

PI: David Bender

NCT05445778

GOG-3086 REFRaME-O1:
Criteria: Recurrent, platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer; FOLR1 expression ≥25% on central lab screening IHC testing; measurable disease required; Up to 3 prior regimens – no prior FOLR1-targeting ADC; prior bevacizumab required unless contraindicated

PI: David Bender

NCT05870748

OVARIAN CANCER

OPEN

PENDING



ENDOMETRIAL CANCER

NEWLY DIAGNOSED HER2+

NRG-GY026 :
Criteria: stage IA-IVB, non-recurrent, chemo-naive, HER2+ endometrial serous carcinoma or endometrial carcinosarcoma; must have myoinvasive disease; must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration; no prior radiation therapy, biologic, or targeted therapy for endometrial cancer

PI: David Bender

NCT05256225

RECURRENT dMMR

NRG-GY025:
Criteria: Recurrent MMR-deficient endometrial cancer; serous and carcinosarcoma subtypes excluded; measurable or detectable disease required; patients may have received up to 2 prior lines of systemic therapy; prior anti-PD1/PD-L1 therapy is allowed if given in combination with chemotherapy or radiation therapy in adjuvant or primary metastatic/recurrent settings; must have had a complete response and have disease progression/relapse with treatment-free interval of 12 months or more from last dose of therapy with immune check inhibition

PI: David Bender

NCT05112601

ENDOMETRIAL CANCER

OPEN

PENDING



CERVICAL CANCER



METASTATIC

BGB-A317-A3055-101: A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

PI: Muhammad Furqan

NCT05935098

GERM CELL TUMOR

LOW OR STANDARD RISK

AGCT1531 :
Criteria: Low risk stage I immature teratoma (IT);
site: ovarian; tumor markers: alpha-FP =< 1,000 ng/mL, beta-HCG institutional normal; all ages
Standard risk 2 (SR2)
Site: ovarian; stage: COG stage II and III, FIGO stage IC, II and III; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age < 25

PI: David Dickens

NCT03067181

INTERMEDIATE OR POOR RISK

AGCT1532:
Criteria: Histologically or cytologically confirmed germ cell; or Exceptionally raised tumour markers (AFP ≥ 1000ng/mL and/or HCG ≥ 5000 IU/L) without histologic or cytologic confirmation in the rare case where pattern of metastases consistent with GCT, high tumour burden, and a need to start therapy urgently; Primary arising in testis, ovary, retro-peritoneum, or mediastinum; Intermediate or poor prognosis as defined by IGCCC classification3

PI: David Dickens

NCT02582697

BRCA1 OVARIAN CANCER RISK REDUCTION

OPEN

PENDING



Head and Neck Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

HEAD AND NECK CANCER

OPEN PENDING

HNSCC

ADJUVANT

GSK-221530 JADE: Has newly diagnosed unresected LA histologically confirmed HNSCC of the oral cavity, oropharynx, hypopharynx or larynx and completed cisplatin plus radiotherapy with curative intent and has no evidence of distant metastatic disease.

PI: Doug Laux

NCT06256588

HEAD AND NECK CANCER

OPEN PENDING



HEAD AND NECK CANCER

OPEN

PENDING



HEAD AND NECK CANCER

OPEN

PENDING

NASOPHARYNGEAL

Study to Evaluate BL-B01D1: Has measurable disease; LVEF ≥50%; must have received platinum and PD1

PI: Muhammad Furqan

NCT05983432

HEAD AND NECK CANCER

OPEN PENDING

THYROID CANCER

EA3231:
Dedifferentiated thyroid cancer; BRAF V600E+; must have been previously treated with or deemed ineligible for treatment with Iodine-131; must have had prior treatment lenvatinib and/or sorafenib

PI: Doug Laux

NCT06475989

NON-MELANOMA SKIN CANCER

CUTANEOUS SQUAMOUS CELL

1L

COMBINE-EGFR-1: A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors

PI: Doug Laux

NCT04626635

MERKEL, BASAL, SCC

Replimune IGNYTE
Criteria: Locally advanced or metastatic NMSC not considered treatable by surgery; must have received 8 wks of anti-PD1/PDL1 as their last line of therapy and progressed while on treatment

PI: Doug Laux

NCT: 03767348

MERKEL CELL

HCRN MCC20-443
Criteria: Histological or cytological evidence of Merkel cell cancer per AJCC, 8th ed; presence of somatostatin receptors by Ga-68 dotatate imaging; progress on treatment with anti-PD1/L1 administered either as monotherapy or in combination with other check point inhibitors or other therapies

PI: Doug Laux

NCT: 05583708

Leukemia Clinical Trials

Clinical Trials Hotline: 319-353-8155

ACUTE MYELOID LEUKEMIA (AML)

OPEN PENDING

NEWLY DIAGNOSED

MM1YA-S01:
Newly diagnosed untreated AML, high-risk AML; therapy-related AML, AML with myelodysplasia related changes are eligible; FLT3 and t(9;22) excluded

PI: Prajwal Dhakal

NCT05554406

MM1YA-CTG01:
Must have been assigned to this study based on presence of an actionable mutation following screening on MYELOMATCH; Age 18-59 at time of induction

PI: Prajwal Dhakal

NCT05554393

KO-MEN-007
Criteria: Newly diagnosed or relapsed/refractory AML with NPM1 or KMT2A rearrangement

PI: Grerk Sutamtewagul

NCT: 05735184

OncoVerity
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

PI: Grerk Sutamtewagul

NCT06384261

MYELOMATCH:
A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH

PI: Prajwal Dhakal

NCT05564390

MM1OA-EA02:
Must have been assigned to this study based screening from MYELOMATCH; must be ≥60 years of age or <60 and better served by azanucleoside-based therapy rather than intensive therapy based on clinical status

PI: Prajwal Dhakal

NCT06317649

ACUTE MYELOID LEUKEMIA (AML)

OPEN PENDING



MALIGNANT HEME (OTHER)

NEWLY DIAGNOSED MDS

SY-1425-301
Criteria: Must be RARA-positive based on investigational assay; diagnosis of MDS according to WHO classification and classified as very high, high, or intermediate risk per IPSS

PI: Grerk Sutamtewagul

NCT: 04797780

MF, MDS, MDS/MPN, ET

LIMBER
Criteria: Received at least 1 prior line of therapy; R/R or intolerant to the last therapy; no therapy that would provide clinical benefit in the opinion of the investigator

PI: Kittika Poonsombudlert

NCT04279847

ANY MYELOID MALIGNANCY

CA055-001
Criteria: Moderate or severe hepatic impairment as defined by National Cancer Institute Organ Dysfunction Working Group criteria

PI: Grerk Sutamtewagul

NCT: 05209295

Lymphoma Clinical Trials

Clinical Trials Hotline: 319-353-8155

LARGE CELL LYMPHOMAS

OPEN PENDING



LARGE CELL LYMPHOMAS

OPEN PENDING



LARGE CELL LYMPHOMAS

OPEN PENDING



MANTLE CELL LYMPHOMA

FRONTLINE

A052101:

A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients (Age ≥ 70 or ≥ 60 with selected comorbidities) with Mantle Cell Lymphoma

PI: Umar Farooq

NCT: 05976763

RELAPSED/REFRACTORY

SGN35T-001:

An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

PI: Eric Mou

NCT06120504

ELM-2

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated

PI: Umar Farooq

NCT: 03888105

BGB-16673

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

PI: Eric Mou

NCT: 05006716

FOLLICULAR LYMPHOMA

OPEN

PENDING



CLL/SLL



FRONTLINE

BELLWAVE-011:

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PI: Eric Mou

NCT06136559

RELAPSED/REFRACTORY

BGB-16673

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

PI: Eric Mou

NCT: 05006716

HODGKIN LYMPHOMA



FRONTLINE

AHOD2131:

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

PI: David Dickens

NCT05675410

RELAPSED/REFRACTORY

BTCRC HEM 15-027:

Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

PI: Umar Farooq

NCT03681561

SGN35T-001:

An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

PI: Eric Mou

NCT06120504

T-CELL LYMPHOMA



FRONTLINE

A051902:

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative (<10%) Peripheral T-Cell Lymphomas

PI: Umar Farooq

NCT: 04803201

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

PI: Brian Link

NCT01787409

RELAPSED/REFRACTORY

SGN35T-001:

An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

PI: Eric Mou

NCT06120504

OTHER LYMPHOMAS

RELAPSED/REFRACTORY

Marginal Zone Lymphoma

ELM-2

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated

PI: Umar Farooq

NCT: 03888105

Marginal Zone Lymphoma

JNJ-90009530

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

PI: Umar Farooq

NCT05784441

Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia

BGB-16673

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

PI: Eric Mou

NCT: 05006716

Melanoma Clinical Trials

Clinical Trials Hotline: 319-353-8155

CUTANEOUS MELANOMA

OPEN PENDING



UVEAL MELANOMA



1L

IDE196-002
Criteria: HLA-A*02:01 negative patients (Testing can be done at U of Iowa)
Treatment naïve patients with metastatic uveal melanoma

Investigational Agent: Darovasertib + Crizotinib vs investigator choice

PI: Asad Javed

NCT05987332

Checkpoint Inhibitor Naive

RP2-202
Criteria: Disease not amenable to surgical resection; at least 1 measurable and injectable tumor of ≥ 1 cm in longest diameter (≥ 1.5 cm in the shortest axis for LN); willing to provide tumor biopsy samples

PI: Asad Javed

NCT06581406

Myeloma Clinical Trials

Clinical Trials Hotline: 319-353-8155

MULTIPLE MYELOMA

OPEN

PENDING

NEWLY DIAGNOSED

CARTITUDE-6
Phase 3
DVRd->Cilta-cel vs DVRd->auto stem cell in first line

No prior treatment for MM

ASCT is part of intended treatment plan

PI: Christopher Strouse

NCT05257083

S2209
Phase 3 evaluation comparing up front 3 drug regimens with single or double agent maintenance

1 cycle of non-daratumumab allowed prior to enrollment

Myeloma Frailty Score= frail or intermediate risk regardless of age

PI: Hira Shaikh

NCT05561387

AMMbition
Phase 2 evaluation of combination of Dara-VRd + bispecific antibody + Cilta-cel in limited duration regimen

1 cycle of Dara-VRd permitted prior to enrollment

Standard risk MM

PI: Christopher Strouse

NCT06577025

MULTIPLE MYELOMA (CONT'D)

OPEN | PENDING

RELAPSED/REFRACTORY

Ascorbic Acid + Melphalan
High Dose Ascorbic Acid is hypothesized to have synergy with melphalan. This is a phase 1 dose escalation trial.

3+ prior lines of therapy
Prior exposure to IMiD, PI, Anti-CD38 antibody required

PI: Christopher Strouse

NCT: 03602235

C1071020 – Elranatamab + Carfilzomib / anti-CD47 antibody
Testing combinations with anti-BCMA bispecific antibody.

Arm 1: Elra + Carf
1-3 prior lines
Prior carfilzomib is OK

Arm 2: Elra + anti-CD47
3+ prior lines of therapy
Refractory to IMiD, PI, anti-CD38 antibody

PI: Hira Shaikh

NCT: 05675449

P-BCMA-ALLO1
Allogeneic anti-BCMA CAR-T cells.

EITHER
- 2+ prior lines of therapy
- Refractory to PI, IMiD, anti-CD38 antibody

OR
- 3+ prior lines of therapy
- Exposure to PI, IMiD, anti-CD38 antibody

PI: Christopher Strouse

NCT: 04960579

QUINTESSENTIAL
Autologous anti-GPRC5d CAR-T cells

3+ prior lines
Prior treatment with anti-BCMA therapy is **required**

PI: Christopher Strouse

NCT: 06121843

LimiTEC

Limited duration therapy of teclistamab

Patients achieving VGPR or better after 6 cycles of teclistamab (less than 9).

Telephone consenting and remote monitoring is possible (no need to visit Iowa City)

PI: Hira Shaikh

NCT05932680

MonumenTAL-8
Combination anti-GPRC5d bispecific antibody + anti-BCMA CAR T cells for high risk myeloma

3+ prior lines
Exposure to IMiD, PI, anti-CD38 antibody
"High Risk" myeloma = 1 of:
- Cyto t[4;14, t[14;16], or -17p
- Baseline ISS Stage III
- Extramedullary plasmacytoma

No prior anti-BCMA therapy

PI: Christopher Strouse

NCT06550895

MULTIPLE MYELOMA

OPEN

PENDING

SMOLDERING MYELOMA

Ecog-Acrin 173
Phase 3 Pre-emptive tx for high risk smoldering myeloma
Dara-Rd x2 years
Vs
Rd x 2 years

"High Risk" SMM = 2 of these:
- >2.0 g/dl m-protein
- Cyto: +1q, t[4;14], -17p, -13q
- >20% PCs in marrow
- Involved light chains 20x greater than uninvolved

Dx in last 1 year, no myeloma defining criteria

PI: Christopher Strouse

NCT: 03937635

Neuroendocrine Clinical Trials

Clinical Trials Hotline: 319-353-8155

NEUROENDOCRINE CANCER



GEP-NET

ACTION-1:
Criteria: Progressed after 2 to 4 cycles of Lutathera at 200 mCi/cycle; Measurable disease requirement

PI: David Bushnell

NCT05477576

VMT-α-NET-T101
Criteria: . CrCl ≥ 60 mL/min. Treatment naïve. Measurable disease requirement.

PI: Yusuf Menda

NCT05636618

PHEOCHROMOCYTOMA, PARAGANGLIOMA

VMT-α-NET-T101
Criteria: . CrCl ≥ 60 mL/min. Treatment naïve. Measurable disease requirement.

PI: Yusuf Menda

NCT05636618

Sarcoma Clinical Trials

Clinical Trials Hotline: 319-353-8155

SARCOMA


OPEN
PENDING
SOFT TISSUE SARCOMA
Boast:
Criteria: Metastatic/LA disease; at least 1 line of prior systemic therapy
PI: John Rieth
NCT04040205
TVEC:
Criteria: Locally advanced STS that are unresectable with clear wide margins for which preoperative radiotherapy is considered appropriate
PI: John Rieth
NCT06660810
LEIOMYOSCARCOMA
Polaris:
Criteria: Grade 2 or 3 LMS STS that would be standardly treated with gem or gem/doc; previous treatment with up to 2 systemic regimens with at least 1 systemic regimen containing doxorubicin
PI: Mohammed Milhem
NCT: 05712694
UNDIFFERENTIATED PLEOMORPHIC
Palbociclib + Pembrolizumab
Criteria: Any patient with locally advanced, unresectable or undifferentiated pleomorphic sarcoma who has progressed on at least 1 prior line of therapy and for who pembrolizumab is a next appropriate standard treatment.
PI: Mohammed Milhem
NCT: 06113809
EA7222:
Criteria: UPS or related poorly differentiated sarcoma; metastatic/unresectable; no prior treatment with anthracycline
PI: John Rieth
NCT06422806

SARCOMA

OPEN PENDING

ANGIOSARCOMA

IGNYTE
Criteria: locally advanced or metastatic disease; at least 1 measurable and injectable lesion; must have received 8 weeks of anti-PD1 as last line of therapy and progressed while on treatment

PI: Doug Laux

NCT: 03767348

CHONDROSARCOMA

CHONQUER
Criteria: LA/metastatic chondrosarcoma grades 1, 2, 3, not eligible for a curative resection; have received 0-1 prior systemic treatments in LA/metastatic setting

PI: John Rieth

NCT06127407

INBRX-109
Criteria: Conventional chondrosarcoma, unresectable or metastatic (clear-cell, mesenchymal, extraskeletal myxoid, myxoid, and dedifferentiated chondrosarcoma are not eligible)

PI: Mohammed Milhem

NCT: 04950075

Thoracic Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

NON-SMALL CELL LUNG CANCER



NON-SMALL CELL LUNG CANCER

OPEN | PENDING



SMALL CELL LUNG CANCER



1L

MOZART:
Criteria: Extensive disease IV SCLC, or T3-4 disease due to multiple lung nodules that are too extensive for radiation; No prior systemic therapy for small-cell lung cancer, with the following exceptions: Up to one cycle of platinum doublet chemotherapy with or without durvalumab is allowed up to 4 weeks prior to registration on this study

PI: Muhammad Furqan

NCT05903092

2ND LINE+

M23-385: Criteria: Histologically or cytologically confirmed SCLC that is relapsed or refractory (R/R) following at least 1 prior platinum-containing chemotherapy and with no curative therapy available

PI: Muhammad Furqan

NCT05599984

Study to Evaluate BL-B01D1: Has measurable disease; LVEF ≥50%

PI: Muhammad Furqan

NCT05983432

BTCRC-LUN20-462
Criteria: Histologically or cytologically documented diagnosis of extensive stage SCLC and have progressed or recurred after platinum-based chemotherapy with immunotherapy; max of 2 prior lines of systemic therapy in the metastatic setting

PI: Muhammad Furqan

NCT: 04919382

Cancer Services – Quad Cities Clinical Trials

Clinical Trials Hotline: 319-353-8155

THORACIC CANCER

OPEN

PENDING

SCLC

BTCRC-LUN20-462
Criteria: Histologically or cytologically documented diagnosis of extensive stage SCLC and have progressed or recurred after platinum-based chemotherapy with immunotherapy; max of 2 prior lines of systemic therapy in the metastatic setting

PI: Muhammad Furqan

NCT: 04919382

BREAST CANCER

TRIPLE NEGATIVE

SCARLET: T2-T4, N0, M0 or T1-T3, N1-2, M0; no prior systemic therapy or radiation therapy with curative intent for current breast cancer

PI: Sneha Phadke

NCT05929768

Optim-ICE: T1cN1-2 or T2-4N0-2; no residual disease or LN after neoadjuvant therapy; neoadjuvant chemo+pembro x 6 cycles; < 12 weeks between surgery and randomization

PI: Sneha Phadke

NCT05812807

ER+

Cambria: must have had definitive locoregional therapy +/- adjuvant systemic therapy; completed at least 2 yrs (but no more than 5) of adjuvant ET (and is still receiving)

PI: Sneha Phadke

NCT05774951

ADE-MI: HR+HER2- who are prescribed abemaciclib

PI: Sneha Phadke

NCT06169371

BR009: premenopausal; postoperative pT1-3; ipsilateral nodes pN0 or pN1; if node negative, oncotype DX RS RS 21-25 or 16-20 with high clinical risk disease; if 1-3 nodes+ oncotype DX RS 26

PI: Sneha Phadke

NCT05879926

HEAD AND NECK CANCER

OPEN

PENDING

THYROID CANCER

EA3231:
Dedifferentiated thyroid cancer; BRAF V600E+; must have been previously treated with or deemed ineligible for treatment with Iodine-131; must have had prior treatment lenvatinib and/or sorafenib

PI: Doug Laux

NCT06475989

GI CANCER



COLON

NRG-GI008
Criteria: T1-3, N1/N1c confirmed adenocarcinoma with RO resection; no radiographic evidence of overt metastatic disease; distal extent of tumor ≥12 cm from anal verge on colonoscopy or above peritoneal reflection as documented during surgery or on path specimen; must have had en bloc complete gross resection of tumor (curative resection); microsatellite stable or intact mismatch repair proteins through CLIA approved testing

PI: Saima Sharif

NCT: 05174169

GEJ

A022102
Criteria:
Unresectable or metastatic HER2- adenocarcinoma of esophagus, GEJ, or stomach; no prior treatment for unresectable or metastatic disease

PI: Saima Sharif

NCT05677490

MULTIPLE MYELOMA

SMOLDERING MYELOMA

Ecog-Acrin 173
Phase 3 Pre-emptive tx for high risk smoldering myeloma
Dara-Rd x2 years
Vs
Rd x 2 years

"High Risk" SMM = 2 of these:
- >2.0 g/dl m-protein
- Cyto: +1q, t[4;14], -17p, -13q
- >20% PCs in marrow
- Involved light chains 20x greater than uninvolved

Dx in last 1 year, no myeloma defining criteria

PI: Christopher Strouse

NCT: 03937635

NEWLY DIAGNOSED

S2209
Phase 3 evaluation comparing up front 3 drug regimens with single or double agent maintenance

No prior treatment for MM

Myeloma Frailty Score= frail or intermediate risk regardless of age

PI: Hira Shaikh

NCT05561387